COVID-19 Vaccine Skycovion Among Raft Of New EU Filings

EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.

The EMA is reviewing new drugs for potential use in the EU • Source: Alamy

The European Medicines Agency has begun reviewing EU marketing authorization applications (MAAs) for a raft of new products, including SK bioscience’s COVID-19 vaccine, Skycovion, and Byondis’s trastuzumab duocarmazine, for treating HER2-positive metastatic breast cancer.

Skycovion (GBP510), which was approved in South Korea in June, is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet